|
2026 Conference Publication First-line (1L) olomorasib + pembrolizumab in patients with KRAS G12C–mutant advanced NSCLC, and PD-L1 expression 0-49%, from the dose optimization cohorts of LOXO-RAS-20001 and SUNRAY-01Chan, Bryan Anthony, Peters, Solange, Leon, Luis, Yamada, Tadaaki, Makani, Neeharika Srivastava, Huang, Wen-Tsung, Spyratos, Dionisios, Roubec, Jaromir, Reinmuth, Niels, Sacher, Adrian G., Spira, Alexander I., Singhal, Nimit, Takeuchi, Shinji, Murciano-Goroff, Yonina R., Zhou, Yanhong, Fink, Aaron Alan, Merced, Alyson, Willard, Melinda D., Visseren Grul, Carla M. and Johnson, Melissa Lynne (2026). First-line (1L) olomorasib + pembrolizumab in patients with KRAS G12C–mutant advanced NSCLC, and PD-L1 expression 0-49%, from the dose optimization cohorts of LOXO-RAS-20001 and SUNRAY-01. 2026 ASCO Annual Meeting, Chicago, IL United States, 29 May-2 June 2026. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2026.44.16_suppl.8628 |
|
2026 Conference Publication Olomorasib+Pembrolizumab in KRAS G12C-Mutant NSCLC: Results from LOXO-RAS-20001 and SUNRAY-01Johnson, M L, Mateos, L L, Yamada, T, Makani, N, Chan, B, Huang, W-T, Spyratos, D, Roubec, J, Reinmuth, N, Sacher, A, Spira, A, Singhal, N, Takeuchi, S, Murciano-Goroff, Y, Zhou, Y, Fink, A, Fasnacht, N, Willard, M, Visseren-Grul, C, Peters, S and Wesseler, C (2026). Olomorasib+Pembrolizumab in KRAS G12C-Mutant NSCLC: Results from LOXO-RAS-20001 and SUNRAY-01. STUTTGART: Georg Thieme Verlag KG. doi: 10.1055/s-0046-1816480 |
|
2025 Conference Publication Phase II trial of first-line durvalumab and chemotherapy in patients with extra-pulmonary small cell carcinomaKok, P. S., Chan, B., Zhang, A., O'byrne, K., Aberoumoud, M., Thavaneswaran, S., Lin, F. P., Kansara, M., Corpuz, T., Wheeler, P., Simes, J., Thomas, D. M. and Lee, C. K. (2025). Phase II trial of first-line durvalumab and chemotherapy in patients with extra-pulmonary small cell carcinoma. AMSTERDAM: ELSEVIER. doi: 10.1016/j.annonc.2025.10.1018 |
|
2025 Conference Publication Primary Endpoint Results from SHERLOCK: a Phase 2 trial of Sotorasib, Bevacizumab and Chemotherapy in Advanced<i> KRAS</i> G12C NSCLCLee, C. K., Zhou, D. d. -x., Brown, C. S. B., Bray, V., Ding, P., Itchins, M., Hughes, B. G. M., Houghton, B., Chan, B., Black, A., Solomon, B. J., Roberts-Thomson, R., Mersiades, A. J., Parakh, S., Bain, N., Yip, S., Barton, K., Cummins, M. M., Wall, M., Goodwin, A., Stockler, M., Pavlakis, N., John, T. and Arulananda, S. (2025). Primary Endpoint Results from SHERLOCK: a Phase 2 trial of Sotorasib, Bevacizumab and Chemotherapy in Advanced KRAS G12C NSCLC. NEW YORK: ELSEVIER SCIENCE INC. |
|
2025 Conference Publication Efficacy and Safety of 1L Olomorasib Plus Pembrolizumab in KRAS G12C-Mutant NSCLC: Results From LOXO-RAS-20001 and SUNRAY-01Johnson, M. L., Mateos, L. L., Yamada, T., Makani, N., Chan, B., Huang, W. T., Spyratos, D., Roubec, J., Reinmuth, N., Sacher, A., Spira, A. I., Singhal, N., Takeuchi, S., Murciano-Goroff, Y. R., Zhou, Y., Fink, A. A., Merced, A., Willard, M. D., Visseren-Grul, C. and Peters, S. (2025). Efficacy and Safety of 1L Olomorasib Plus Pembrolizumab in KRAS G12C-Mutant NSCLC: Results From LOXO-RAS-20001 and SUNRAY-01. NEW YORK: ELSEVIER SCIENCE INC. |
|
2024 Conference Publication Building regional clinical trial capacity and identifying unmet needs: 10-year audit of medical oncology clinic trials activated at the Sunshine Coast University Hospital and Health Service (SCHHS)Zhang, Betty Y., Donohoe, Carrie, Catuogno, Christelle, Turner, Cassie and Chan, Bryan A. (2024). Building regional clinical trial capacity and identifying unmet needs: 10-year audit of medical oncology clinic trials activated at the Sunshine Coast University Hospital and Health Service (SCHHS). HOBOKEN: WILEY. |
|
2024 Conference Publication Queensland state-wide patterns and access to EGFR mutation testing for metastatic, non-squamous non-small cell lung cancer (non-SQ NSCLC) from 2014 to 2021Niranjan, Navin, Yang, Zane, Mason, Robert, Guan, Tracey, Chan, Bryan A. and Sanmugarajah, Jasotha (2024). Queensland state-wide patterns and access to EGFR mutation testing for metastatic, non-squamous non-small cell lung cancer (non-SQ NSCLC) from 2014 to 2021. HOBOKEN: WILEY. |
|
2024 Conference Publication Reducing preventable emergency visits: results from the Oncology Nurse Practitioner-led Rapid Access Clinic (RACE) service at a tertiary regional cancer centreMazza, Cassandra, O'Neill, Martina, Ringshaw, Kacy, Collins, Kelly, O'Riley, Lily, Danielsen-Jensen, Madeline, Bradford, Natalie, Gavin, Nicole, Brunelli, Vanessa N. and Chan, Bryan A. (2024). Reducing preventable emergency visits: results from the Oncology Nurse Practitioner-led Rapid Access Clinic (RACE) service at a tertiary regional cancer centre. COSA's 51st Annual Scientific Meeting, Gold Coast, QLD, Australia, 13-15 November 2024. Chichester, West Sussex, United Kingdom: Wiley-Blackwell Publishing. doi: 10.1111/ajco.14116 |
|
2024 Conference Publication Do patient characteristics influence the first-line chemotherapy regimen for adenocarcinoma of the pancreas?Allen, Michael, Chan, Bryan A., Walpole, Euan, Clark, Jon, Youlden, Danny, Dhanda, Pardeep, Dunn, Nathan and Cossio, Danica (2024). Do patient characteristics influence the first-line chemotherapy regimen for adenocarcinoma of the pancreas?. HOBOKEN: WILEY. |
|
2024 Conference Publication EGFR mutation testing trends for patients with metastatic, non-squamous non-small cell lung cancer (non-SQ NSCLC) in Queensland, Australia from 2014-2021Yang, Zane, Niranjan, Navin, Guan, Tracey, Mason, Robert, Chan, Bryan Anthony and Sanmugarajah, Jasotha (2024). EGFR mutation testing trends for patients with metastatic, non-squamous non-small cell lung cancer (non-SQ NSCLC) in Queensland, Australia from 2014-2021. 2024 ASCO Annual Meeting, Chicago, IL United States, 31 May - 4 June 2024. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2024.42.16_suppl.e13505 |
|
2024 Conference Publication Exploring the lung cancer microbiome using metagenomics in an Australian cohortBaird, T., Olagoke, O., Chan, B., Bint, M., Pattison, A., Fraser, T., Bell, P., Greathouse, L., Stone, J., Sarovich, D. and Price, E. (2024). Exploring the lung cancer microbiome using metagenomics in an Australian cohort. HOBOKEN: WILEY. |
|
2024 Conference Publication Peptide receptor radionuclide therapy (PRRT) in patients with neuroendocrine neoplasms: A prospective multi-site study evaluating quality of life and objective responseCehic, G., Kong, G., Corsini, N., Chan, D., Pavlakis, N., Bailey, D., Mercurio, J., Laidlaw, D., Chan, B., Patel, D. and Hayes, A. (2024). Peptide receptor radionuclide therapy (PRRT) in patients with neuroendocrine neoplasms: A prospective multi-site study evaluating quality of life and objective response. 21st Annual Conference of the European-Neuroendocrine-Tumor-Society (ENETS), Vienna Austria, Mar 13-15, 2024. HOBOKEN: WILEY. |
|
2023 Conference Publication Utilisation of the integrated exercise physiology and physiotherapy service at a tertiary cancer centre by people with lung cancerGibbons, Kathryn, Forbes, Curtis, Houston, Kathleen and Chan, Bryan A. (2023). Utilisation of the integrated exercise physiology and physiotherapy service at a tertiary cancer centre by people with lung cancer. HOBOKEN: WILEY. |
|
2023 Conference Publication Understanding the current therapeutic landscape for non-metastatic non-small cell lung cancer in QueenslandLehman, Margot, Sanmugarajah, Jasotha, Dhanda, Pardeep, Nath, Artika, Rawson, Neal, Chan, Bryan, Negrello, Theresa and Windsor, Morgan (2023). Understanding the current therapeutic landscape for non-metastatic non-small cell lung cancer in Queensland. HOBOKEN: WILEY. |
|
2023 Conference Publication Exploring the lung microbiome using metagenomics in an Australian cohort of people with lung cancerChan, Bryan, Baird, Timothy, Olagoke, Olusola, Bint, Michael, Pattison, Andrew, Bell, Peter, Greathouse, K. Leigh, Stone, Joshua, Sarovich, Derek S. and Price, Erin P. (2023). Exploring the lung microbiome using metagenomics in an Australian cohort of people with lung cancer. HOBOKEN: WILEY. |
|
2023 Conference Publication A pilot optimal pre-habilitation pathway for people with lung cancer on treatment in a regional cancer centreGibbons, Kathryn, Forbes, Curtis, Houston, Kathleen and Chan, Bryan A. (2023). A pilot optimal pre-habilitation pathway for people with lung cancer on treatment in a regional cancer centre. HOBOKEN: WILEY. |
|
2022 Conference Publication COVID-19 vaccine uptake and hesitancy amongst Australian patients with breast cancerHudson, Jo, McCartney, Amelia, Kwok, Alastair, Grech, Lisa, Tognela, Annette, Nott, Louise, King, Rossa, Nguyen, Mike, Bain, Nathan, Chan, Bryan, Harris, Samuel, Chau, Hieu, Hamad, Nada, Underhill, Craig, Williams, Janne, Webber, Kate, Day, Daphne and Segelov, Eva (2022). COVID-19 vaccine uptake and hesitancy amongst Australian patients with breast cancer. HOBOKEN: WILEY. |
|
2022 Conference Publication Real-world outcomes for patients with pleural mesothelioma: A multisite retrospective cohort studyChow, Kar Ven Cavan K. V. C. C., Turner, CassieC. T., Hughes, BrettB. H., Houston, Kathleen K. H., Lwin, Zarnie Z. L. and Chan, Bryan B. C. (2022). Real-world outcomes for patients with pleural mesothelioma: A multisite retrospective cohort study. HOBOKEN: WILEY. |
|
2022 Conference Publication Exploring attitudes towards COVID-19 vaccination in adults with haematological malignanciesBlennerhassett, Richard, Hamad, Nada, Grech, Lisa, Forsyth, Cecily, Jagger, Jacqueline, Opat, Stephen, Harris, Samuel, Chan, Bryan, Kwok, Alastair, Nguyen, Mike, Bain, Nathan, Day, Daphne and Segelov, Eva (2022). Exploring attitudes towards COVID-19 vaccination in adults with haematological malignancies. HOBOKEN: WILEY. |
|
2022 Conference Publication The role of thoracic radiotherapy (TRT) in the era of chemoimmunotherapy for extensive stage small cell lung cancer (ES-SCLC)Turner, Cassie L., Prasetio, Tito E., O'Berine, Shannon, Anderson, Georgina, Hughes, Brett G. M., Vignarajah, Dinesh, Castelli, Joanne, Lwin, Zarnie, Houston, Kathleen and Chan, Bryan A. (2022). The role of thoracic radiotherapy (TRT) in the era of chemoimmunotherapy for extensive stage small cell lung cancer (ES-SCLC). HOBOKEN: WILEY. |
